Markets
EBS

Revance's Botulinum Toxin Type A in Cervical Dystonia Study

A generic image of a person holding out their hands
Credit: Shutterstock photo

Revance Therapeutics, Inc.RVNC announced that it has started dosing patients with RT002 (botulinum toxin type A injection) in a phase II study for the treatment of cervical dystonia (a neurological muscle movement disorder).

The open-label, sequential, dose-escalating study will evaluate the safety, efficacy and duration of effect of a single application of the candidate, in patients with moderate-to-severe isolated cervical dystonia symptoms of the neck. Interim data from the study is expected in 2016.

According to information provided by the company, several hundred thousand adults and children are affected with cervical dystonia in the U.S. The company estimates that the worldwide market for treating muscle movement disorders with botulinum toxins, including cervical dystonia, was approximately $900 million in 2014.

We note that, Revance is also studying RT002 in the phase II BELMONT study for the treatment of glabellar (frown) lines. Results from the study are expected in the fourth quarter of 2015. Moreover, the company believes that RT002 can potentially address additional therapeutic indications in movement disorders, pain management, urology, ophthalmology and other indication in which more targeted delivery or longer duration is required.

Meanwhile, Revance continues to progress on the development of other pipeline candidates. Currently, the company is evaluating RT001 (topical formulation of botulinum toxin type A) in phase III pivotal study for the treatment of lateral canthal lines, or crow's feet (interim data expected in the first half of 2016) and in phase II for the treatment of primary axillary hyperhidrosis (interim data expected by year-end).

Revance carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Emergent BioSolutions, Inc. EBS , Nexvet Biopharma Public Limited Co. NVET and Regeneron Pharmaceuticals, Inc. REGN , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

REVANCE THERAP (RVNC): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

EMERGENT BIOSOL (EBS): Free Stock Analysis Report

NEXVET BIOPHARM (NVET): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EBS REGN RVNC

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More